Financial Performance - Revenue for the year ended December 31, 2025, increased by approximately RMB 9.75 million or 3.74% to approximately RMB 270.4 million compared to RMB 260.6 million for the year ended December 31, 2024[4]. - Net profit attributable to the owners of the parent company for the year ended December 31, 2025, was approximately RMB 17.9 million, a decrease of approximately RMB 7.03 million or 28.16% from RMB 24.97 million for the year ended December 31, 2024[4]. - The company reported a basic and diluted earnings per share of approximately RMB 0.03 for 2025[5]. - The group reported a net profit of RMB 17,937 thousand for 2025, down from RMB 24,967 thousand in 2024, reflecting a decline of approximately 28.1%[17]. - The pre-tax profit for 2025 was RMB 19,524 thousand, down 23.4% from RMB 25,497 thousand in 2024[37]. - The effective tax rate for the group in 2025 was significantly lower due to various tax incentives, with total tax expenses amounting to RMB 1,587 thousand compared to RMB 530 thousand in 2024[38]. - The company declared an interim dividend of RMB 5,756 thousand for 2025, compared to no dividend in 2024[39]. - Net profit decreased by approximately 28.16% from RMB 25.0 million for the year ending December 31, 2024, to RMB 17.9 million for the year ending December 31, 2025, with a net profit margin declining from approximately 9.6% to 6.6%[64]. Revenue Breakdown - The revenue breakdown by solution category shows that the Precision Omnichannel Marketing Solutions generated RMB 121.85 million, accounting for 45.07% of total revenue, while the Physician Platform Solutions generated RMB 92.96 million, accounting for 34.38%[3]. - Revenue from customer contracts for 2025 reached RMB 270,374 thousand, an increase of 3.1% from RMB 260,623 thousand in 2024[30]. - The breakdown of revenue for 2025 shows that medical services contributed RMB 92,958 thousand, precision omnichannel marketing solutions contributed RMB 121,848 thousand, real-world research solutions contributed RMB 43,208 thousand, and data and AI solutions contributed RMB 12,360 thousand[31]. - Revenue from precision omnichannel marketing solutions rose by 5.87% to approximately RMB 121.8 million in 2025, compared to RMB 115.1 million in 2024[50]. - Revenue from RWS solutions grew by 20.84% to approximately RMB 43.2 million in 2025, up from RMB 35.8 million in 2024[53]. - Revenue from physician platform solutions decreased by 15.32% to approximately RMB 93.0 million in 2025, down from RMB 109.8 million in 2024[52]. Assets and Liabilities - Total non-current assets increased to RMB 31,305,000 from RMB 28,269,000, representing an increase of 7.3% year-over-year[19]. - Current assets rose to RMB 1,354,406,000, up from RMB 1,320,987,000, reflecting a growth of 2.5%[19]. - Trade receivables increased significantly to RMB 41,329,000, a 25.2% rise from RMB 33,026,000[19]. - Total liabilities increased to RMB 201,357,000 from RMB 179,361,000, marking a rise of 12.3%[19]. - Net asset value reached RMB 1,181,037,000, compared to RMB 1,169,688,000, indicating a growth of 1.0%[20]. - The company had no bank borrowings or other interest-bearing debts as of December 31, 2025, resulting in a debt-to-equity ratio of zero[69]. Operational Strategy - The company is focusing on enhancing its capabilities in artificial intelligence, integrating AI technology into product development, content production, and operational management to improve efficiency and cost-effectiveness[8]. - The introduction of two new intelligent evidence-based solutions, SeekEvidence and DeepEvidence, aims to enhance the company's service capabilities in evidence generation, dissemination, and decision-making[9][10]. - The company is leveraging over 20 years of accumulated medical content resources and evidence-based medicine capabilities to drive new business growth and maintain its leading position in digital medical services[9]. - The company is committed to optimizing its business structure and upgrading its capabilities to focus on long-term value and growth potential in response to industry trends and customer needs[8]. - The group is focusing on evidence-driven marketing and real-world research to support the high-quality development of innovative drugs[14]. - The company aims to accelerate the commercialization of AI technologies in 2025, with expectations for rapid revenue growth from AI services[15]. - The company is committed to building a global healthcare ecosystem by integrating digital and medical services, enhancing international service models and technical capabilities[16]. Market Position and Expansion - The Chinese pharmaceutical industry is undergoing significant reforms, with ongoing policy support for high-quality development of innovative drugs and digital transformation, creating favorable conditions for the company's growth[7]. - The group has over 5.82 million registered users on its doctor platform, with approximately 3.56 million certified doctors and a coverage rate of 71% for associate and chief physicians[11]. - The group has served 628 pharmaceutical companies, achieving a 100% coverage rate of the global top 20 pharmaceutical companies[11]. - The establishment of a Southeast Asia headquarters in Singapore is part of the strategy to deepen market penetration in the region[16]. - The company successfully expanded cooperation with domestic and international growth-oriented innovative pharmaceutical companies, driving revenue growth[49]. - The company is exploring market expansion opportunities to enhance its competitive edge[93]. Research and Development - The group's R&D expenses for 2025 were RMB 30,661 thousand, up 31.9% from RMB 23,238 thousand in 2024, indicating a focus on innovation and development[36]. - R&D expenses increased to approximately RMB 30.7 million for the year ending December 31, 2025, from RMB 7.5 million, driven by investments in AI technology and product development[59]. - The company is focused on research and development (R&D) to enhance its product offerings and market position[93]. - The company aims to leverage real-world data through Real World Studies (RWS) to improve clinical applications and outcomes[93]. - The company is focused on integrating evidence-based medicine into its research methodologies[93]. Corporate Governance - The company was listed on the Hong Kong Stock Exchange on April 27, 2023[22]. - The financial statements were prepared in accordance with International Financial Reporting Standards, reflecting a commitment to transparency and compliance[23]. - The board confirmed compliance with corporate governance codes as of December 31, 2025, and will continue to monitor governance practices[76]. - The board of directors includes both executive and independent non-executive members, ensuring diverse governance[93]. - The company is committed to corporate governance as per the guidelines outlined in the Listing Rules[92].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 梅斯健康控股有限公司 董事會主席及執行董事 張發寶博士 香港，2026年3月19日 於本公告日期，本公司董事會包括執行董事張發寶博士、李欣梅博士、王帥先生及 程亮先生；非執行董事為閆盛楓先生；以及獨立非執行董事為劉濤女士、余明陽先 生及劉耀坤先生。 董事會會議日期 梅斯健康控股有限公司（「本公司」，連同其附屬公司及合併聯屬實體統稱「本集團」） 董事會（「董事會」）兹通告，本公司謹定於2026年3月31日（星期二）舉行董事會會 議，以（其中包括）考慮及批准本集團截至2025年12月31日止的經審核年度業績及其 刊發，及審議派發末期股息（如有）之建議，以及處理其他事項。 承董事會命 ...

FF301 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年3月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | 本月底法定/註冊股本總額： USD 1,500,000 第 1 頁 共 10 頁 v 1.2.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證 ...

Group 1 - The company, Meis Health (02415), announced that Ms. Wang Xin has resigned from her position as a non-executive director due to other work commitments [1] - The resignation will take effect from February 6, 2026 [1]

Group 1 - The core point of the article is that Meiz Health (02415.HK) announced the resignation of non-executive director Wang Xin, effective from February 6, 2026, due to other work commitments [1] Group 2 - The resignation indicates a potential shift in the company's governance structure, which may impact its strategic direction [1] - The announcement highlights the importance of board composition in corporate governance and decision-making processes [1] - The timing of the resignation, set for 2026, suggests that the company is planning for a transition period [1]

MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 閆盛楓先生 獨立非執行董事 劉濤女士 余明陽先生 劉耀坤先生 董事會設立三個委員會。下表載列該等委員會成員詳情。 （於開曼群島註冊成立之有限公司） （股份代號：2415） 董事名單以及其角色及職能 梅斯健康控股有限公司（「本公司」）董事會（「董事會」）成員載列如下。 執行董事 張發寶博士 （董事會主席） 李欣梅博士 （本公司首席執行官） 王帥先生 （本公司聯席首席執行官） 程亮先生 非執行董事 | | 董事委員會 | | | | | --- | --- | --- | --- | --- | | 董事 | | 審核委員會 | 薪酬委員會 | 提名委員會 | | 張發寶博士 | | | M | | | 李欣梅博士 | | | | M | | 王帥先生 | | | | | | 程亮先生 | | | | | | 閆盛楓先生 | | | | | | 劉濤女士 | | C | M | | | 余明陽先生 | | M | C | M | | 劉耀坤先生 | | M | | C | 附註： C 相關董事委員會主席 M 相關董事委員會 ...

Core Viewpoint - Meiz Health (02415) announced the resignation of Ms. Wang Xin as a non-executive director, effective from February 6, 2026, due to her need to undertake other work commitments [1] Company Summary - Ms. Wang Xin's resignation is attributed to her obligations related to other work matters [1]

MedSci Healthcare Holdings Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 承董事會命 梅斯健康控股有限公司 董事會主席及執行董事 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 非執行董事辭任 梅斯健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，王欣女士（「王 女士」）因須承擔其他工作事務，已辭任非執行董事，自2026年2月6日起生效。 王女士已確認彼與董事會並無意見分歧，且亦無與彼辭任董事有關的事項須敦請本 公司股東或香港聯合交易所有限公司垂注。 董事會謹此衷心感謝王女士於任期內為本公司作出的寶貴貢獻。 張發寶博士 香港，2026年2月6日 於本公告日期，董事會包括執行董事張發寶博士、李欣梅博士、王帥先生及程亮先 生；非執行董事閆盛楓先生；以及獨立非執行董事劉濤女士、余明陽先生及 劉耀坤先生。 ...

呈交日期: 2026年2月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 梅斯健康控股有限公司（於開曼群島註冊成立的有限公司） | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02415 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 15,000,000,000 | USD | | 0.0001 USD | | 1,500,000 | 本月底法定/註冊 ...

Core Viewpoint - The recent stock transfer of Mace Health (02415) indicates a significant shift in shareholder structure, with a market value of HKD 88.21 million, representing 10.53% of the company [1] Financial Performance - Mace Health reported a revenue of RMB 125 million for the mid-term of 2025, reflecting a year-on-year growth of 13.2% [1] - The net profit reached RMB 13.239 million, showing a substantial increase of 5238.3% compared to the previous year [1] - The basic earnings per share were recorded at 2.45 cents, with a proposed interim dividend of 1.1 Hong Kong cents per share [1] Industry Insights - The growth in total revenue is attributed to the recovery in the pharmaceutical industry and the accelerated transformation of domestic pharmaceutical companies towards evidence-driven marketing models [1] - There is an increasing demand for precise omnichannel marketing solutions, driven by the industry's shift [1]